CoChat
Sign Up
Cited by 7Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer

Open access
Bennouna, Jaafar·2017·Future Oncology
DOI 10.2217/fon-2017-0240
Open this paper in CoChat — free accountOpen PDF

Abstract

afatinib • combination • EGFR • non-small

Integrity signals

Registry

Crossref · 10.2217/fon-2017-0240

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The combination of afatinib with EGFR antibodies or bevacizumab has shown promise but some may be associated with considerable treatment-related toxicities.

    “Other approaches include the combination of afatinib with EGFR antibodies or bevacizumab, which have shown promise but some may be associated with considerable treatment-related toxicities.”

    From Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [105]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bennouna, J.
Affiliations
Centre Hospitalier Universitaire de Nantes (FR)
Corresponding author
Bennouna, Jaafar
ORCID
Bennouna, Jaafar
Venue
Future Oncology
Publisher
Informa UK Limited
Published
2017-06-28
Volume
13
Issue
21
Pages
1829-1833
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
DOI
10.2217/fon-2017-0240
OpenAlex
W2728181306
Cited by
7
References
3
Citations by year
2023: 1 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 1
FWCI
1.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Future Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
afatinib, EGFR mutation, non-small cell lung cancer, combination therapy, tyrosine kinase inhibitors
MeSH terms
Afatinib, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Clinical Trials as Topic, Humans, Lung Neoplasms, Mutation, Quinazolines, Signal Transduction, Treatment Outcome, Protein Kinase Inhibitors, Molecular Targeted Therapy, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review